The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
Open accessAbstract
Major depressive disorder (MDD) is a chronic, burdensome, highly prevalent disease that is characterized by depressed mood and anhedonia. MDD is especially burdensome as approved monoamine antidepressant treatments have weeks-long delays before clinical benefit and low remission rates. In the past 2 decades, a promising target emerged to improve patient outcomes in depression treatment: glutamatergic signaling. This narrative review provides a high-level overview of glutamate signaling in synaptogenesis and neural plasticity and the implications of glutamate dysregulation in depression. Based on this preclinical evidence implicating glutamate in depression and the rapid improvement of depression with ketamine treatment in a proof-of-concept trial, a range of N-methyl-d-aspartate (NMDA)-targeted therapies have been investigated. While an array of treatments has been investigated in registered phase 2 or 3 clinical trials, the development of most of these agents has been discontinued. Multiple glutamate-targeted antidepressants are actively in development, and two are approved. Nasal administration of esketamine (Spravato®) was approved by the US Food and Drug Administration (FDA) in 2019 to treat adults with treatment-resistant depression and in 2020 for adults with MDD with acute suicidal ideation or behavior. Oral combination dextromethorphan–bupropion (AXS-05, Auvelity® extended-release tablet) was FDA approved in 2022 for the treatment of MDD in adults. These approvals bolster the importance of glutamate in depression and represent an exciting breakthrough in contemporary psychiatry, providing new avenues of treatment for patients as first-line therapy or with either poor response or unacceptable side effects to monoaminergic antidepressants. Major depressive disorder (MDD) is a common disease defined by sadness and a loss of interest or pleasure in activities. Depression treatments include therapy and antidepressant medication. Most available antidepressants affect the same types of chemicals that communicate in the brain (neurotransmitters) called monoamines. Unfortunately, these medicines can take weeks to work for some people and many still have depression symptoms with treatment. To provide more treatment options, new medicines have been studied that impact a different neurotransmitter in the brain, that is, glutamate. Glutamate, the most abundant neurotransmitter, is important for the growth of new brain cell connections, and there are changes in glutamate in people with depression versus people without depression. In 2000, the first small study in people showed that ketamine, a medicine targeting glutamate, quickly improved depression symptoms. Safety risks, including dissociation and sedation, require supervised administration and management guidance. Since 2000, about 20 glutamate-targeted medicines have been tested in human clinical trials. Two of these are approved as antidepressants. The medicine esketamine, which is inhaled up the nose at a clinic under medical supervision, is approved for the adjunctive treatment of people with MDD whose symptoms do not improve with other treatments or who have suicidal thoughts or actions (brand name Spravato®). The combination medicine dextromethorphan–bupropion is a swallowed tablet taken twice daily that is an approved monotherapy to treat adults with MDD (brand name Auvelity®). The approval of these drugs helps show the importance of glutamate in depression and provides more options for people with depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Glutamate signaling in neuroplasticity and synaptogenesis. Akt protein kinase B, AMPAR α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, BDNF brain-derived neurotrophic factor, EAAT excitatory amino acid transporter, EF2 eukaryotic elongation factor 2, ERK extracellular signal-regulated kinases, Gln glutamine, Glu glutamate, mGluR metabotropic glutamate receptor, mTOR mammalian target of rapamycin, NMDAR N-methyl-d-aspartate receptor, P phosphorylated, TrkB tropomyosin receptor kinase B, vGLUT vesicular glutamate transporter. Modified from Lener et al. 2017 [162] and Henter et al. 2021 [14]. Figure illustration elements modified from Servier Medical Art (2022) by Servier (https://smart.servier.com, used under a Creative Commons Attribution 4.0 License)](https://figures.cochat.ai/paper-figures/68ef3373bc64473084336bf4d3222e9b/glutamatergic-modulators-for-major-depression-from-theory-to-clinical-use-figure-1.jpg)
![Fig. 2 Timeline of registered trials of glutamate-targeted drugs for treatment of depressiona. aFigure includes phase 2, 3, and 4 trials registered on ClinicalTrials.gov for the treatment of MDD or TRD as detailed in Online Resource 1, Supplementary Table 1. bThe first placebo-controlled, double-blind trial of ketamine in seven people with depression, conducted in 2000, was not registered on ClinicalTrials.gov [64]. cIntranasal esketamine is approved by the FDA, TPD, EMA, and TGA as an adjunctive treatment for TRD and/or for MDD with suicidal ideation/behavior or psychiatric emergency. dAXS-05 is approved to treat MDD in adults by the FDA. EMA European Medicines Agency, FDA US Food and Drug Administration, MDD major depressive disorder, NMDA N-methyl d-aspartate, TGA Australia’s Therapeutic Goods Administration, TPD Canada’s Therapeutic Products Directorate, TRD treatment-resistant depression](https://figures.cochat.ai/paper-figures/edf97bb37e3e4d8cbb81601f2d178b1a/glutamatergic-modulators-for-major-depression-from-theory-to-clinical-use-figure-2.jpg)
![Fig. 3 Response and remission rates with adjunctive intranasal esketamine in TRANSFORM-2 triala,b. aTRANSFORM-2 (NCT02418585) investigated adjunctive flexibly dosed intranasal esketamine versus adjunctive placebo with a newly initiated oral SNRI or SSRI antidepressant, in patients with TRD in a 28-day double-blind treatment phase. bPercentages shown are the proportion of patients remaining at visit [127]. ADT antidepressant, IN intranasal, MADRS Montgomery-Åsberg Depression Rating Scale, SNRI serotonin-norepinephrine reuptake inhibitor, SSRI selective serotonin reuptake inhibitor, TRD treatment-resistant depression, NR not reported](https://figures.cochat.ai/paper-figures/e2bc8d1fcaa9445b8a3691f901fd5e97/glutamatergic-modulators-for-major-depression-from-theory-to-clinical-use-figure-3.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Esketamine provides a more NMDAR-centered entry into the induction pathway described above, producing rapid clinical effects but also transient dissociation and sympathomimetic effects [45,46,47,49,52,55,56].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Common adverse effects include dissociation, dizziness, and blood pressure (BP) elevation [52,53,55].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
The American Psychological Association
Langfeld, H. S. (1919) · Science · doi:10.1126/science.49.1254.51 · Cited by 7,475
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 2×
“Depression is especially burdensome due to the low rates of remission associated with current monoamine antidepressant treatments [15, 16].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 1×
“…of eukaryotic elongation factor 2 (eEF2), allowing for protein translation [45]. mTOR activation thus increases the expression of synaptic proteins vital for the formation, maturation, and function of synaptic spines and can lead to increases in the density of dendritic spines [44–47].”
BackgroundRisks of all-cause and suicide mortality in mental disorders: a meta-review
Chesney, E., Goodwin, G. M., & Fazel, S. (2014) · World Psychiatry · doi:10.1002/wps.20128 · Cited by 2,115 · cited 2×
“These efficacy limitations with monoamine antidepressants may also demoralize patients and contribute to the increased risk of suicide in people with depression [8].”
BackgroundGlutamate: A Neurotransmitter in Mammalian Brain
Fonnum, F. (1984) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1984.tb09689.x · Cited by 1,992
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737 · cited 1×
“Major depressive disorder (MDD) is a highly prevalent disease, and depressive disorders have been a leading cause of chronic disease burden worldwide for the past 3 decades [1, 2].”
Background
Research works printed but not linked: 2
- Réus GZ, Quevedo J, Lúcia S, Rodrigues A. Mtor signaling in the neuropathophysiology of depression: current evidence. J Recept Ligand Channel Res. 2015;65:78.
- Paterson B, Fraser H, Wang C, et al. A randomized, double-blind, placebo-controlled, sequential parallel study of cerc-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment. National Network of Depression Centers Annual Conference; Ann Arbor, MI. 2015.
Cited by
d’Andrea, G., Cavallotto, C., Pettorruso, M., Lorenzo, G. D., Carullo, R., Berardis, D. D., Rosso, G., Barlati, S., Martiadis, V., Tamagnini, G., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116655 · Cited by 26
Self-citationAntos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
Cheng, M. C. H., Dri, C. E., Ballum, H., Valentino, K., Cheung, W., Teopiz, K. M., Wong, S., & McIntyre, R. S. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.119 · Cited by 17
Self-citationPharmacological Monotherapy for Depressive Disorders: Current and Future—A Narrative Review
Gao, K., Oruc, E. B., & Koparal, B. (2025) · Medicina · doi:10.3390/medicina61040558 · Cited by 14
Nagpurkar, K., Ghive, P., Kale, M. B., Nistane, N. T., Taksande, B. G., Umekar, M. J., & Trivedi, R. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.05.022 · Cited by 12
Metadata
- Authors
- McIntyre, R. S., & Jain, R.
- Affiliations
- University of Toronto (CA)
- Texas Tech University (US)
- Corresponding author
- Jain, Rakesh
- Venue
- CNS Drugs
- Published
- 2024-08-16
- Volume
- 38
- Issue
- 11
- Pages
- 869-890
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC11486832
- OpenAlex
- W4401654837
- Cited by
- 69
- References
- 133
- Citations by year
- 2026: 33 · 2025: 34 · 2024: 2
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Axsome Therapeutics., Inc.
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, glutamate signaling, NMDA receptor, ketamine, esketamine, treatment-resistant depression, synaptogenesis, neuroplasticity, antidepressant drug development, anhedonia, suicidal ideation, intranasal administration, drug safety and tolerability
- MeSH terms
- Animals, Antidepressive Agents, Major Depressive Disorder, Humans, Ketamine, Excitatory Amino Acid Agents, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glutamatergic Modulators for Major Depression from Theory to Clinical Use. https://app.cochat.ai/papers/10.1007/s40263-024-01114-y
- The paper
- McIntyre, R. S., & Jain, R. (2024). Glutamatergic Modulators for Major Depression from Theory to Clinical Use. CNS Drugs. https://doi.org/10.1007/s40263-024-01114-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.